<DOC>
	<DOCNO>NCT00068757</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop tumor cell divide stop grow die . Lonafarnib may stop growth tumor cell block enzymes necessary growth . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining lonafarnib trastuzumab paclitaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lonafarnib give together trastuzumab paclitaxel treat patient HER2/neu-overexpressing stage IIIB , stage IIIC , stage IV breast cancer .</brief_summary>
	<brief_title>Lonafarnib , Trastuzumab , Paclitaxel Treating Patients With HER2/Neu-Overexpressing Stage IIIB , Stage IIIC , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose lonafarnib combination trastuzumab ( Herceptin® ) paclitaxel patient HER2/neu-overexpressing stage IIIB , IIIC , IV breast cancer . - Determine qualitative quantitative toxicity regimen patient . Secondary - Determine pharmacokinetic profile drug patient . - Correlate pharmacodynamics pharmacokinetics regimen patient . - Correlate pharmacokinetics pharmacodynamics regimen observe toxicity patient . - Determine response regimen patient measurable disease . OUTLINE : This nonrandomized , open-label , multicenter , dose-escalation study lonafarnib . - Course 1 : Patients receive load dose trastuzumab ( Herceptin® ) IV 90 minute day 1 30 minute day 8 15 . Patients also receive paclitaxel IV 3 hour day 1 . - Course 2 : Patients receive trastuzumab IV 30 minute day 1 , 8 , 15 paclitaxel IV 3 hour day 2 . Patients also receive oral lonafarnib twice daily day 3-21 . - Course 3 subsequent course : Patients receive oral lonafarnib twice daily day 1-21 ; trastuzumab IV 30 minute day 1 , 8 , 15 ; paclitaxel IV 3 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos lonafarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 8 week disease progression . PROJECTED ACCRUAL : A total 3-36 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Stage IIIB , IIIC , IV HER2/neu overexpression 3+ immunohistochemistry 2+ allow positive fluorescent situ hybridization Disease meet follow treatment criterion : Paclitaxel/trastuzumab ( Herceptin® ) may appropriate therapy Anthracycline therapy suitable approach No clinical sign CNS involvement Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 02 OR WHO 02 Life expectancy Not specify Hematopoietic Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL ( 6.2 mmol/L ) Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN ( 5 time ULN liver metastasis present ) AST ALT less 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine clearance least 40 mL/min Cardiovascular Cardiac ejection fraction normal MUGA QTc interval great 440 msec No cardiac dysfunction Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No concurrent severe/unstable systemic disease No infection No circumstance would preclude study participation ( e.g. , alcoholism substance abuse ) No psychological , familial , sociological , geographical condition would preclude study compliance followup PRIOR CONCURRENT THERAPY : Biologic therapy More 1 year since prior trastuzumab No concurrent prophylactic growth factor Chemotherapy More 1 year since prior paclitaxel More 4 week since prior chemotherapy Endocrine therapy More 1 day since prior hormonal therapy More 2 day since prior highdose chronic steroid More 2 day since prior ethinyl estradiol No concurrent highdose chronic steroid No concurrent ethinyl estradiol Radiotherapy More 4 week since prior radiotherapy Surgery Not specify Other More 2 day since prior administration concurrent CYP3A4 inducer inhibitor , include follow : Gestodene Itraconazole Ketoconazole Cimetidine Erythromycin Carbamazepine Phenobarbital Phenytoin Rifampin Sulfinpyrazone No concurrent grapefruit juice No concurrent anticancer agents No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>